Literature DB >> 19138766

POMT2 intragenic deletions and splicing abnormalities causing congenital muscular dystrophy with mental retardation.

Akiko Yanagisawa1, Céline Bouchet, Susana Quijano-Roy, Sandrine Vuillaumier-Barrot, Nigel Clarke, Sylvie Odent, Diana Rodriguez, Norma B Romero, Makiko Osawa, Tamao Endo, Ana Lia Taratuto, Nathalie Seta, Pascale Guicheney.   

Abstract

BACKGROUND: Alpha-dystroglycanopathies are a group of congenital muscular dystrophies (CMDs) with autosomal recessive inheritance characterized by abnormal glycosylation of alpha-dystroglycan. Although six genetic causes have been identified (FKTN, POMGNT1, POMT1, POMT2, FKRP, and LARGE) many alpha-dystroglycanopathy patients remain without a genetic diagnosis after standard exon sequencing. To date POMT2 mutations have been identified in CMD cases with a wide range of clinical severities from Walker-Warburg syndrome to limb girdle muscular dystrophy without structural brain or ocular involvement.
METHODS: We analyzed POMT2 in six CMD patients, who had severe diffuse muscle weakness, generalized joint contractures, microcephaly, severe mental retardation and elevated CK levels. Eye involvement was absent or limited to myopia or strabismus. We sequenced the coding regions of POMT2 using genomic DNA and cDNA generated from blood lymphocytes or B lymphoblastoid cell lines. Quantitative PCR analysis of genomic DNA was used to identify and determine the breakpoints of large deletions.
RESULTS: We report five novel mutations in POMT2, four of which were outside of coding exons, two large genomic deletions and two intronic single base substitutions that induced aberrant mRNA splicing.
CONCLUSIONS: Large scale DNA rearrangements (such as large deletions) and cryptic splice mutations, that can be missed on standard sequencing of genomic DNA, may be relatively common in POMT2. Additional techniques, such as sequencing of cDNA are needed to identify all mutations. These results also confirm that POMT2 mutations are an important cause of the less severe alpha-dystroglycanopathy phenotypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19138766     DOI: 10.1016/j.ejmg.2008.12.004

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  6 in total

Review 1.  The o-mannosylation pathway: glycosyltransferases and proteins implicated in congenital muscular dystrophy.

Authors:  Lance Wells
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

2.  Novel POMGNT1 point mutations and intragenic rearrangements associated with muscle-eye-brain disease.

Authors:  S Saredi; A Ardissone; A Ruggieri; E Mottarelli; L Farina; R Rinaldi; E Silvestri; C Gandioli; S D'Arrigo; F Salerno; L Morandi; P Grammatico; C Pantaleoni; I Moroni; M Mora
Journal:  J Neurol Sci       Date:  2012-05-02       Impact factor: 3.181

Review 3.  Congenital muscular dystrophies: a brief review.

Authors:  Enrico Bertini; Adele D'Amico; Francesca Gualandi; Stefania Petrini
Journal:  Semin Pediatr Neurol       Date:  2011-12       Impact factor: 1.636

Review 4.  Clinical and Molecular Spectrum of Muscular Dystrophies (MDs) with Intellectual Disability (ID): a Comprehensive Overview.

Authors:  Malihe Mohamadian; Mandana Rastegar; Negin Pasamanesh; Ata Ghadiri; Pegah Ghandil; Mohsen Naseri
Journal:  J Mol Neurosci       Date:  2021-11-02       Impact factor: 3.444

5.  Structure of the eukaryotic protein O-mannosyltransferase Pmt1-Pmt2 complex.

Authors:  Lin Bai; Amanda Kovach; Qinglong You; Alanna Kenny; Huilin Li
Journal:  Nat Struct Mol Biol       Date:  2019-07-08       Impact factor: 15.369

6.  Diagnostic approach to the congenital muscular dystrophies.

Authors:  Carsten G Bönnemann; Ching H Wang; Susana Quijano-Roy; Nicolas Deconinck; Enrico Bertini; Ana Ferreiro; Francesco Muntoni; Caroline Sewry; Christophe Béroud; Katherine D Mathews; Steven A Moore; Jonathan Bellini; Anne Rutkowski; Kathryn N North
Journal:  Neuromuscul Disord       Date:  2014-01-09       Impact factor: 4.296

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.